Intellikine Gets Two, Two, Two Partners In One With Infinity PI3 Kinase Deal
This article was originally published in The Pink Sheet Daily
Ex-U.S. commercialization comes along with the Infinity partnership through Infinity's "big brother" relationship with Mundipharma.
You may also be interested in...
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.